OBI-992 獲FDA核准展開一/二期臨床試驗
January 03, 2024 05:00 ET
|
OBI Pharma Inc.
台灣台北電, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技（4174.TWO）今（3）日宣布，旗下以TROP2為標靶、自行研發的抗體藥物複合體（ADC）新藥OBI-992，已獲美國食品藥物管理局（FDA）核准一/二期臨床試驗申請，以評估其安全性及療效。 ...
OBI-992 获FDA核准展开一/二期临床试验
January 03, 2024 05:00 ET
|
OBI Pharma Inc.
台湾台北电, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技（4174.TWO）今（3）日宣布，旗下以TROP2为标靶、自行研发的抗体药物复合体（ADC）新药OBI-992，已获美国食品药物管理局（FDA）核准一/二期临床试验申请，以评估其安全性及疗效。 ...
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
January 03, 2024 05:00 ET
|
OBI Pharma Inc.
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an...
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
January 02, 2024 08:00 ET
|
Sterling Infosystems, Inc
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
November 20, 2023 04:00 ET
|
AKAMPION
- Phase I data show safety and tolerability at clinically significant dose levels- New class of anti-infectives to treat infections with Gram-negative bacteria JERUSALEM, Israel, November 20,...
Medical Devices Testing Services Market Size Worth USD 22.43 Billion in 2032 | Emergen Research
November 15, 2023 12:24 ET
|
Emergen Research
Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The global Medical Devices Testing Services Market will be worth USD 22.43 Billion by 2032, according to a current analysis by Emergen Research. The...
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis
November 13, 2023 02:00 ET
|
Blueberry Therapeutics
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary...
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
November 08, 2023 04:54 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to...